secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0001193125-26-017945
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital
--------------------------------------------------------------------------------

- Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.
- New loans mature January 1, 2030; interest rate is prime + 2.25% (min 9.25%, capped at 10.25%).
- End-of-term fee of 5.95% of aggregate principal; additional tranches tied to clinical, approval, and commercial milestones.
- Issued 40,850 warrants at $9.18/share to Lenders as part of initial draw; up to 204,248 warrants possible if fully drawn.
- Loan secured by substantially all assets including intellectual property; Hercules Capital acts as agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/engn-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-017945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer